Parkinson’s disease treatment pharmaceutical company South Korea with Mediforum

Parkinson’s medication biomedical engineering today by Mediforum? The 4 institutions conducted clinical trials on 125 patients and as with previous preclinical animal studies, clinical trials and research results, significant improvements were observed in the Myungmin test group. Clinically significant safety issues and side-effects were not observed. Tests were conducted on Myungmin to ensure purity of the individual compounds, including tests for the detection of heavy metals and high performance liquid chromatography to ensure no other foreign substances contaminate the product. Find even more info on memory loss treatment.

Myungminwon is a liquid based herbal supplement, produced under a carefully controlled enrichment process in an advanced FDA-compliant and registered manufacturing facility, which enhances memory and improves concentration and cognitive functions. It has the highest concentration of the active natural compounds that work to fight beta amyloid plaque, stimulate neurogenesis, improve overall brain health while also aiding in enhancing memory and concentration. The liquid form allows for easier consumption for individuals who suffer from dysphagia or have difficulty with swallowing.

Dementia and Alzheimer’s Disease are progressive disorders that can strike members of any family. When your loved one is diagnosed with Dementia or Alzheimer’s Disease, your role in the family may change to a caregiver as you navigate the progression of the disease together. While each family’s experience managing these progressive diseases is unique, commonalities exist that can help you provide better care for your loved one who suffers from a degenerative and ultimately debilitating disease.

Living with Alzheimer’s disease is a reality for over 5 million Americans today. Although this eventually debilitating disease was first identified more than 100 years ago, we still have few leads as to what causes Alzheimer’s and how to treat it effectively. What is known about Alzheimer’s is that the disease essentially suffocates the brain with a plaque which causes loss of cognitive function over time. Most physicians treat Alzheimer’s like a brain disease and prescribe pharmaceuticals to slow down plaque buildup and preserve brain function for as long as possible. This conventional approach to treatment only begins after a person has been diagnosed with Alzheimer’s disease, which unfortunately may be some time after the damage to the brain has already started.

Mediforum’s commitment is to make a positive contribution to public health and to change the social perception of infectious diseases by providing early screening for HPV and other STDs. We aim to be a leader in the research and development of new drugs to treat intractable diseases using naturally derived materials to open new vistas in biomedical sciences and achieve the pinnacle of drug safety. On September 27, 2018, Mediforum has received approval for the phase 3 clinical trial for dementia treatment, the first to reach such milestone in Korea. Discover additional details on https://www.mediforum.co/.